CN109069583B - 使用cd24蛋白治疗瘦素缺乏病状 - Google Patents

使用cd24蛋白治疗瘦素缺乏病状 Download PDF

Info

Publication number
CN109069583B
CN109069583B CN201780008474.2A CN201780008474A CN109069583B CN 109069583 B CN109069583 B CN 109069583B CN 201780008474 A CN201780008474 A CN 201780008474A CN 109069583 B CN109069583 B CN 109069583B
Authority
CN
China
Prior art keywords
ser
thr
pro
val
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201780008474.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN109069583A (zh
Inventor
Y.刘
P.郑
M.德文波特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncoimmune Inc
Original Assignee
Oncoimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncoimmune Inc filed Critical Oncoimmune Inc
Publication of CN109069583A publication Critical patent/CN109069583A/zh
Application granted granted Critical
Publication of CN109069583B publication Critical patent/CN109069583B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2264—Obesity-gene products, e.g. leptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CN201780008474.2A 2016-02-02 2017-02-02 使用cd24蛋白治疗瘦素缺乏病状 Expired - Fee Related CN109069583B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662290202P 2016-02-02 2016-02-02
US62/290,202 2016-02-02
PCT/US2017/016120 WO2017136492A1 (en) 2016-02-02 2017-02-02 Use of cd24 proteins for treating leptin-deficient conditions

Publications (2)

Publication Number Publication Date
CN109069583A CN109069583A (zh) 2018-12-21
CN109069583B true CN109069583B (zh) 2021-09-21

Family

ID=59500202

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780008474.2A Expired - Fee Related CN109069583B (zh) 2016-02-02 2017-02-02 使用cd24蛋白治疗瘦素缺乏病状

Country Status (8)

Country Link
US (2) US10799558B2 (enExample)
EP (1) EP3411062B1 (enExample)
JP (1) JP6938835B2 (enExample)
KR (1) KR20180120145A (enExample)
CN (1) CN109069583B (enExample)
CA (1) CA3012466A1 (enExample)
SG (1) SG11201806338SA (enExample)
WO (1) WO2017136492A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018217659A1 (en) * 2017-05-22 2018-11-29 Oncoimmune, Inc. Methods of use of soluble cd24 for treating immune related adverse events in cancer therapies
SG11202007815TA (en) * 2018-03-05 2020-09-29 Oncoimmune Inc Methods of use of soluble cd24 for treating acquired immune deficiency syndrome (hiv/aids)
WO2019236474A1 (en) 2018-06-04 2019-12-12 Oncoimmune, Inc. Methods of use of cd24 for the prevention and treatment of leukemia relapse
US20220000974A1 (en) * 2019-02-06 2022-01-06 Oncolmmune, Inc. Targeting CD24-Siglec Interactions for Treating Subjects with Prediabetes or Diabetes
WO2020163529A1 (en) * 2019-02-06 2020-08-13 Oncoimmune, Inc. Targeting cd24-siglec interactions for the treatment and prevention of nonalcoholic steatohepatitis

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102869369A (zh) * 2010-04-28 2013-01-09 肿瘤免疫股份有限公司 利用可溶性cd24治疗类风湿性关节炎的方法
CN104244733A (zh) * 2011-08-30 2014-12-24 学术医学中心 预防和/或治疗胰岛素抗性的方法
CN104903450A (zh) * 2012-11-05 2015-09-09 普隆奈治疗公司 寡核苷酸癌症疗法的给药和施用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001259792B2 (en) * 2000-03-29 2005-12-22 The Ohio State University Research Foundation Methods of blocking tissue destruction by autoreactive T cells
WO2004106495A2 (en) * 2003-05-29 2004-12-09 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102869369A (zh) * 2010-04-28 2013-01-09 肿瘤免疫股份有限公司 利用可溶性cd24治疗类风湿性关节炎的方法
CN104244733A (zh) * 2011-08-30 2014-12-24 学术医学中心 预防和/或治疗胰岛素抗性的方法
CN104903450A (zh) * 2012-11-05 2015-09-09 普隆奈治疗公司 寡核苷酸癌症疗法的给药和施用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Leptin in congenital and HIV-associated lipodystrophy;Michael A. Tsoukas等;《Metabolism》;20151231;第64卷(第1期);第47-59页 *
Loss of CD24 in Mice Leads to Metabolic Dysfunctions and a Reduction in White Adipocyte Tissue;Nicholas A. Fairbridge等;《Plos one》;20151104;第10卷(第4期);e0141966 *

Also Published As

Publication number Publication date
CA3012466A1 (en) 2017-08-10
KR20180120145A (ko) 2018-11-05
EP3411062B1 (en) 2020-11-25
JP2019506408A (ja) 2019-03-07
WO2017136492A1 (en) 2017-08-10
US20190038716A1 (en) 2019-02-07
JP6938835B2 (ja) 2021-09-22
US10799558B2 (en) 2020-10-13
EP3411062A1 (en) 2018-12-12
EP3411062A4 (en) 2019-09-25
US20210162006A1 (en) 2021-06-03
SG11201806338SA (en) 2018-08-30
CN109069583A (zh) 2018-12-21

Similar Documents

Publication Publication Date Title
CN109069583B (zh) 使用cd24蛋白治疗瘦素缺乏病状
US20250282843A1 (en) Compositions comprising an interleukin construct
CN107531772B (zh) Cd24用于降低低密度脂蛋白胆固醇水平的用途
US10793617B2 (en) Methods of use of soluble CD24 for therapy of rheumatoid arthritis
CN101848735A (zh) 用于药物用途的新型neurturin缀合物
AU2013344973B2 (en) Compositions and methods for the treatment of ectodermal dysplasia
HK40002090A (en) Use of cd24 proteins for treating leptin-deficient conditions
EP1675611B1 (en) Therapeutic applications for c-peptide
HK40002090B (zh) 使用cd24蛋白治疗瘦素缺乏病状
TW202432577A (zh) 投與基於纖連蛋白之支架域蛋白以治療超重、肥胖及相關健康病狀
KR20190126801A (ko) 전신 홍반성 루푸스를 치료하기 위한 가용성 cd24의 사용 방법

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40002090

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20210921